{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=25", "query": { "intervention": "Radiotherapy followed by chemotherapy", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 887, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=26&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Radiotherapy+followed+by+chemotherapy&page=24&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T10:29:50.647Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00795457", "title": "Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Astrocytoma", "Oligo-Astrocytoma", "Glioma" ], "interventions": [ { "name": "GAA/TT-peptide vaccine and poly-ICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ian F. Pollack, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2009-01", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2019-08-30", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 2, "location_summary": "Winston-Salem, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795457" }, { "nct_id": "NCT02525757", "title": "MPDL3280A With Chemoradiation for Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MPDL3280A", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2016-01-26", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02525757" }, { "nct_id": "NCT02010567", "title": "Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "CRLX101", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2013-12", "completion_date": "2019-06-25", "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 6, "location_summary": "Denver, Colorado • Indianapolis, Indiana • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02010567" }, { "nct_id": "NCT00923195", "title": "Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Skin Cancer" ], "interventions": [ { "name": "MART-1: 26-35(27L) Peptide", "type": "DRUG" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "gp100:154-162 Peptide", "type": "DRUG" }, { "name": "Radiation", "type": "PROCEDURE" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Anti-gp 100:154 TCR PBL", "type": "GENETIC" }, { "name": "Anti-MART-1 F5 TCR PBL", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-12", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923195" }, { "nct_id": "NCT02635360", "title": "Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Linda R Duska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 94, "start_date": "2017-02-09", "completion_date": "2022-12-14", "has_results": true, "last_update_posted_date": "2025-07-03", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 8, "location_summary": "Mobile, Alabama • Baltimore, Maryland • St Louis, Missouri + 5 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02635360" }, { "nct_id": "NCT06417190", "title": "Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Tumor" ], "interventions": [ { "name": "Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Leslie Ballas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-01-16", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06417190" }, { "nct_id": "NCT02048020", "title": "Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papilloma Virus Infection", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Verrucous Carcinoma of the Larynx" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 26, "start_date": "2013-12-26", "completion_date": "2017-01-09", "has_results": false, "last_update_posted_date": "2018-08-14", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02048020" }, { "nct_id": "NCT01414608", "title": "Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosquamous Carcinoma", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Stage IB Cervical Cancer AJCC v6 and v7", "Stage IIA Cervical Cancer AJCC v7", "Stage IIB Cervical Cancer AJCC v6 and v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IVA Cervical Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 926, "start_date": "2012-01-09", "completion_date": "2021-07-09", "has_results": true, "last_update_posted_date": "2022-11-07", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 315, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 220 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414608" }, { "nct_id": "NCT00003704", "title": "Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "1999-04", "completion_date": "2003-07", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003704" }, { "nct_id": "NCT00565305", "title": "Healing Touch, Quality of Life, and Immunity During Breast Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Healing Touch", "type": "BEHAVIORAL" }, { "name": "Standard Treatment", "type": "RADIATION" } ], "intervention_types": [ "BEHAVIORAL", "RADIATION" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 150, "start_date": "2003-07", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-10-15T10:29:50.647Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT00565305" } ] }